Joseph J. Eron

57.8k total citations · 15 hit papers
465 papers, 27.9k citations indexed

About

Joseph J. Eron is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Joseph J. Eron has authored 465 papers receiving a total of 27.9k indexed citations (citations by other indexed papers that have themselves been cited), including 389 papers in Infectious Diseases, 298 papers in Virology and 112 papers in Epidemiology. Recurrent topics in Joseph J. Eron's work include HIV/AIDS Research and Interventions (304 papers), HIV Research and Treatment (298 papers) and HIV/AIDS drug development and treatment (246 papers). Joseph J. Eron is often cited by papers focused on HIV/AIDS Research and Interventions (304 papers), HIV Research and Treatment (298 papers) and HIV/AIDS drug development and treatment (246 papers). Joseph J. Eron collaborates with scholars based in United States, United Kingdom and Canada. Joseph J. Eron's co-authors include Myron S. Cohen, Susan A. Fiscus, Douglas D. Richman, Sonia Napravnik, Scott M. Hammer, Pietro Vernazza, Margaret A. Fischl, Paul A. Volberding, Donna M. Jacobsen and Jeffrey Chodakewitz and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Joseph J. Eron

437 papers receiving 27.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

1997 2.1k citations Michael D. Hughes, Judith S. Currier et al. profile →
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

1997 1.5k citations Roy M. Gulick, John W. Mellors et al. profile →
Antiretroviral Treatment of Adult HIV Infection

2012 1.4k citations Melanie Thompson, Joseph J. Eron et al. profile →
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

2012 878 citations Nancie M. Archin, Abigail Liberty et al. profile →
Antiretroviral Treatment of Adult HIV Infection

2008 832 citations Joseph J. Eron, Melanie Thompson et al. profile →
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

2003 716 citations Joseph J. Eron et al. profile →
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1

1997 685 citations Myron S. Cohen, Joseph J. Eron et al. profile →
Brief but Efficient: Acute HIV Infection and the Sexual Transmission of HIV

2004 521 citations Christopher D. Pilcher, Joseph J. Eron et al. The Journal of Infectious Diseases profile →
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2016 478 citations Joseph J. Eron, Melanie Thompson et al. profile →
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2018 401 citations Rajesh T. Gandhi, Davey M. Smith et al. profile →
Antiretroviral Treatment of Adult HIV Infection

2014 352 citations Joseph J. Eron et al. profile →
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2022 320 citations Rajesh T. Gandhi, Davey M. Smith et al. profile →
Selection Bias Due to Loss to Follow Up in Cohort Studies

2015 299 citations Stephen R. Cole, Sonia Napravnik et al. profile →
Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies

2015 298 citations JoAnn D. Kuruc, Cynthia L. Gay et al. The Journal of Infectious Diseases profile →
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

2021 230 citations William A. Fischer, Joseph J. Eron et al. profile →

Peers

Countries citing papers authored by Joseph J. Eron

Since Specialization

Citations

This map shows the geographic impact of Joseph J. Eron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph J. Eron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph J. Eron more than expected).

Fields of papers citing papers by Joseph J. Eron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph J. Eron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph J. Eron. The network helps show where Joseph J. Eron may publish in the future.

Co-authorship network of co-authors of Joseph J. Eron

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph J. Eron. A scholar is included among the top collaborators of Joseph J. Eron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph J. Eron. Joseph J. Eron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	How HIV research drives health innovation in multiple diseases 2025 ·Nature Medicine ·Lawrence Corey, Jirair Ratevosian, Chris Beyrer, Judith S. Currier, Joseph J. Eron, Myron S. Cohen, Steven G. Deeks	0
2	Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral Replication 2024 ·Open Forum Infectious Diseases ·Sook-Kyung Lee, (unknown), Yinyan Xu, Joanna Warren, Shuntai Zhou, Maria Gilleece, Blake M. Hauser, Cynthia L. Gay, JoAnn Kuruc, Nancie M. Archin, Joseph J. Eron, David M. Margolis, Nilu Goonetilleke, Ronald Swanstrom	0
3	COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina 2024 ·Journal of Antimicrobial Chemotherapy ·Heather Henderson, David A. Wohl, William A. Fischer, Luther A. Bartelt, David van Duin, (unknown), (unknown), (unknown), Amanda J Moy, Joseph J. Eron, Sonia Napravnik	2
4	Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine 2023 ·American Journal of Epidemiology ·(unknown), Michael G. Hudgens, Haidong Lu, Stephen R. Cole, Jessie K. Edwards, Adaora A. Adimora, Keri N. Althoff, Michael J. Silverberg, Peter F. Rebeiro, Viviane D. Lima, Vincent C. Marconi, Timothy R. Sterling, Michael A. Horberg, M. John Gill, Mari M. Kitahata, Richard D. Moore, Raynell Lang, Kelly A. Gebo, Charles S. Rabkin, Joseph J. Eron	1
5	Use of Next-Generation Sequencing in a State-Wide Strategy of HIV-1 Surveillance: Impact of the SARS-COV-2 Pandemic on HIV-1 Diagnosis and Transmission 2023 ·The Journal of Infectious Diseases ·Shuntai Zhou, Nathan Long, Matt Moeser, Collin S Hill, Erika Samoff, Victoria Mobley, Simon D. W. Frost, (unknown), Elizabeth Kelly, (unknown), Scott M. Shone, (unknown), (unknown), Joseph J. Eron, Myron S. Cohen, Ronald Swanstrom, Ann M. Dennis	0
6	No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART 2022 ·AIDS ·Adam R. Ward, Allison S. Thomas, (unknown), Szu-Han Huang, Sheila M. Keating, Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Bernard Macatangay, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, R. Brad Jones	3
7	Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses 2022 ·JCI Insight ·Sydney I. Ramirez, Alba Grifoni, Daniela Weiskopf, Urvi M. Parikh, Amy Heaps, Farhoud Faraji, Scott F. Sieg, Justin Ritz, Carlee Moser, Joseph J. Eron, Judith S. Currier, Paul Klekotka, Alessandro Sette, David A. Wohl, Eric S. Daar, Michael D. Hughes, Kara W Chew, Davey M. Smith, Shane Crotty	5
8	Prevalence and risk of residual viremia after ART in low- and middle-income countries 2021 ·Medicine ·Sivaporn Gatechompol, Lu Zheng, Yajing Bao, Anchalee Avihingsanon, Stephen J. Kerr, Nagalingeswaran Kumarasamy, James Hakim, Frank Maldarelli, Robert J. Gorelick, (unknown), Jeffrey D. Lifson, Mina C. Hosseinipour, Joseph J. Eron, Kiat Ruxrungtham	1
9	Fusion designs and estimators for treatment effects 2021 ·Statistics in Medicine ·Alexander Breskin, Stephen R. Cole, Jessie K. Edwards, Ron Brookmeyer, Joseph J. Eron, (unknown)	11
10	LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care 2019 ·Open Forum Infectious Diseases ·Peter F. Rebeiro, Cathy A. Jenkins, Aihua Bian, Jordan E. Lake, Kassem Bourgi, Michael A. Horberg, Richard D. Moore, (unknown), Marina B. Klein, Joseph J. Eron, M. John Gill, Mari M. Kitahata, Sonia Napravnik, Michael J. Silverberg, Ángel M. Mayor, Amanda L. Willig, Michelle Floris-Moore, Timothy R. Sterling, John R. Koethe	13
11	Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort 2018 ·Open Forum Infectious Diseases ·(unknown), Nwora Lance Okeke, Stéphane Hué, Laura Mkumba, (unknown), Sonia Napravnik, Joseph Sebastian, William C. Miller, Joseph J. Eron, Ann M. Dennis	13
12	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells 2018 ·Clinical Infectious Diseases ·Sarah Joseph, Laura P. Kincer, Natalie M. Bowman, Chris Evans, Michael J. Vinikoor, Christopher K. Lippincott, Magnus Gisslén, Serena Spudich, Prema Menezes, Kevin Robertson, Nancie M. Archin, Angela D. M. Kashuba, Joseph J. Eron, Richard W. Price, Ronald Swanstrom	58
13	Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation 2017 ·PLoS Pathogens ·Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Christina M. Lalama, Joshua C. Cyktor, Bernard Macatangay, Charles R. Rinaldo, Sharon A. Riddler, Evelyn Hogg, Catherine Godfrey, Ann C. Collier, Joseph J. Eron, John W. Mellors, (unknown)	130
14	T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy 2017 ·PLoS Pathogens ·Allison S. Thomas, Kimberley Jones, Rajesh T. Gandhi, Deborah K. McMahon, Joshua C. Cyktor, Dora Chan, Szu-Han Huang, Ronald Truong, Alberto Bosque, Amanda B. Macedo, Colin Kovacs, Erika Benko, Joseph J. Eron, Ronald J. Bosch, Christina M. Lalama, Samuel J. Simmens, Bruce D. Walker, John W. Mellors, R. Brad Jones	33
15	HIV-1 Protease, Reverse Transcriptase, and Integrase Variation 2016 ·Journal of Virology ·Soo‐Yon Rhee, Kris Sankaran, Vici Varghese, Mark A. Winters, Christopher B. Hurt, Joseph J. Eron, Neil Parkin, Susan Holmes, Mark Holodniy, Robert W. Shafer	68
16	Immediate antiviral therapy appears to restrict resting CD4 ⁺ cell HIV-1 infection without accelerating the decay of latent infection 2012 ·Proceedings of the National Academy of Sciences ·Nancie M. Archin, Naveen K. Vaidya, JoAnn D. Kuruc, Abigail Liberty, Ann Wiegand, Mary F. Kearney, Myron S. Cohen, John M. Coffin, Ronald J. Bosch, Cynthia L. Gay, Joseph J. Eron, David M. Margolis, Alan S. Perelson	169
17	Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients 2008 ·HIV Clinical Trials ·Robert L. Murphy, Barbara A. da Silva, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick, Melanie Thompson, (unknown), Martin King, George J. Hanna, Scott C. Brun	52
18	Emotional Distress in African American Women with HIV 2007 ·Journal of Prevention & Intervention in the Community ·Margaret Shandor Miles, Diane Holditch‐Davis, Cort A. Pedersen, Joseph J. Eron, Todd A. Schwartz	20
19	Dose Separation Does Not Overcome the Pharmacokinetic Interaction between Fosamprenavir and Lopinavir/Ritonavir 2006 ·Antimicrobial Agents and Chemotherapy ·Amanda Corbett, Kristine B. Patterson, Hsiao‐Chuan Tien, (unknown), Joseph J. Eron, (unknown), Michael L. Lim, Angela D. M. Kashuba	8
20	Acute HIV revisited: new opportunities for treatment and prevention 2004 ·Journal of Clinical Investigation ·Christopher D. Pilcher, Joseph J. Eron, Shannon Galvin, Cynthia L. Gay, Myron S. Cohen	121

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact